ArticleHematological oncology2026
Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma.
Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is usually performed as a curative treatment for adult T-cell leukemia/lymphoma (ATL), following first-line chemotherapy. We conducted a nationwide retrospective study to examine the prognostic impact of donor sources based on transplantation application timings: human leukocyte antigen (HLA)-matched related donor (MRD; n = 253), unrelated donor (URD; n = 656), unrelated cord blood (U-CB; n = 599), and HLA-haploidentical related donor with post-transplant cyclophosphamide (PT-CY; n = 166). In patients with the early application of allo-HSCT (< 100 days from diagnosis), the multivariate analysis showed no significant difference in overall mortality (OM) among all donor sources. Regarding the middle timing of allo-HSCT (100-179 days), the U-CB group showed higher OM than the MRD group (hazard ratio [HR], 1.37; p = 0.013), while the URD and PT-CY groups showed no significant difference in OM with the MRD group. Concerning the late timing of allo-HSCT (180-270 days), the U-CB (HR, 1.88; p = 0.005) and PT-CY groups (HR, 1.90; p = 0.043) showed higher OM than the MRD group, whereas the URD group exhibited comparable OM to the MRD group. The present study demonstrated the differential impact of the graft source based on the timing of allo-HSCT for ATL; therefore, it is important to select an optimal alternative donor based on application timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.